Head-to-head evidence
OPC-61815 vs Tolvaptan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Vasopressin V2 receptor · full Heart Failure pipeline
OPC-61815
Developed by Otsuka Holdings
NCT03772041 · Phase 3 · completed
The trial randomized 294 participants and used double blinding with an active tolvaptan comparator. The primary endpoint was the surrogate measure of change in body weight, and although the reported mean reduction favored OPC-61815 numerically, the statistical significance of the between-group comparison is not stated.
Tolvaptan · Samsca / Jinarc
Marketed by Otsuka Holdings
NCT00071331 · Phase 3 · completed
This large trial randomly assigned 3,600 people with heart failure to tolvaptan or placebo, with treatment assignment masked. Neither primary outcome favoured tolvaptan: all-cause mortality was 25.9% against 26.3% on placebo (hazard ratio 0.98, 95% CI 0.87 to 1.11, p=0.68), and the combined rate of cardiovascular death or heart-failure hospitalisation was 42.0% against 40.2% (hazard ratio 1.04, 95% CI 0.95 to 1.14, p=0.55). The trial was well built and its answer was that tolvaptan did not change these outcomes.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: OPC-61815's landscape · Tolvaptan's landscape